The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.

Alpenglow hosts AACR 2025 Dinner Lecture on endometrial cancer with Dr. Sammy Ferri-Borgogno, showcasing 3D spatial biology ...

Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and ...

NYU Langone Health tapped Alec Kimmelman to succeed Robert Grossman as its next CEO and dean of the NYU Grossman School of ...

In another statement on HHS restructuring, the American Society of Hematology expressed it was "gravely" concerned about ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose ...

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, ...

EGFR has been shown to be over-activated in various human cancers, including colorectal, lung, head and neck, urinary bladder, pancreatic ... therapies for cancer, EGFR inhibitors are increasingly ...

The AACR poster presentation will provide an update on the data in AML patients most recently presented at the American Society of Hematology (ASH) Annual Meeting 2024 showing that ICT01 administered ...

Oregon Health & Science University researchers are developing a promising new blood test that could provide a way to catch pancreatic cancer earlier in more patients. The early screening is called the ...

A novel oral combination drug therapy evaluated at Huntsman Cancer Institute could treat and prevent melanoma spreading to the brain. Brain metastasis is the main cause of death from melanoma.

That is “pretty remarkable,” says Aaron Sasson, who directs the Pancreatic Cancer Center at Stony Brook Medicine in New York and was not involved with the work. Despite facing a notoriously ...